Optieum Biotechnologies
Matsuyama-shi
About Optieum Biotechnologies
Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers. Their proprietary platform technology, Eumbody System™, enables to develop and detect a scFv-based product candidates that specifically bind to, and modulate to optimize the immune-cell function for oncology targets. We are committed to helping patients with severe diseases by bringing life-changing therapies to the patients in need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $11.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2025)
- Website: optieumbio.com
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/optieum-biotechnologies-73553 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.